Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05578976 |
Title | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) |
Acronym | EPCORE DLBCL-2 |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | AbbVie |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | TUR | SWE | SVK | POL | NZL | NLD | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS |